Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of oral orforglipron versus placebo in overweight adults at high risk of obesity-related complications
CTR20263408Phase 3Active
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of orforglipron in Overweight, obesity, sponsored by Eli Lilly and Company. Started Sep 2026; status: active.
02
Drugs
orforglipron
03
Conditions
Overweightobesity
Beyond the preview
Go deeper on CTR20263408.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263408.